BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod SA. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009;115:359-363. [PMID: 18649131 DOI: 10.1007/s10549-008-0128-9] [Cited by in Crossref: 231] [Cited by in F6Publishing: 193] [Article Influence: 17.8] [Reference Citation Analysis]
Number Citing Articles
1 Gao Y, Zhu J, Zhang X, Wu Q, Jiang S, Liu Y, Hu Z, Liu B, Chen X. BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy. PLoS One 2013;8:e52589. [PMID: 23326344 DOI: 10.1371/journal.pone.0052589] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
2 Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Miyazaki T, Oda Y, Otsuka T, Nakamura M. BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer. PLoS One 2016;11:e0167016. [PMID: 27977696 DOI: 10.1371/journal.pone.0167016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
3 Wunderle M, Gass P, Häberle L, Flesch VM, Rauh C, Bani MR, Hack CC, Schrauder MG, Jud SM, Emons J, Erber R, Ekici AB, Hoyer J, Vasileiou G, Kraus C, Reis A, Hartmann A, Lux MP, Beckmann MW, Fasching PA, Hein A. BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Res Treat 2018;171:85-94. [PMID: 29725888 DOI: 10.1007/s10549-018-4797-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
4 Watanabe Y, Maeda I, Oikawa R, Wu W, Tsuchiya K, Miyoshi Y, Itoh F, Tsugawa K, Ohta T. Aberrant DNA methylation status of DNA repair genes in breast cancer treated with neoadjuvant chemotherapy. Genes Cells 2013;18:1120-30. [PMID: 24581343 DOI: 10.1111/gtc.12100] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
5 González-Neira A. Pharmacogenetics of chemotherapy efficacy in breast cancer. Pharmacogenomics 2012;13:677-90. [PMID: 22515610 DOI: 10.2217/pgs.12.44] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
6 Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV. Pancreatic cancer genomics: where can the science take us? Clin Genet 2015;88:213-9. [PMID: 25388820 DOI: 10.1111/cge.12536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
7 Huszno J, Budryk M, Kołosza Z, Nowara E. The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation. Contemp Oncol (Pozn) 2015;19:72-6. [PMID: 26199574 DOI: 10.5114/wo.2015.50014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
8 El Guerrab A, Bamdad M, Bignon Y, Penault-llorca F, Aubel C. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1 -mutated and PTEN -wild-type triple-negative breast cancer cells: TARGETING EGFR IN TRIPLE-NEGATIVE BREAST CANCER. Mol Carcinog 2017;56:1383-94. [DOI: 10.1002/mc.22596] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
9 Sporikova Z, Koudelakova V, Trojanec R, Hajduch M. Genetic Markers in Triple-Negative Breast Cancer. Clin Breast Cancer 2018;18:e841-50. [PMID: 30146351 DOI: 10.1016/j.clbc.2018.07.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 13.7] [Reference Citation Analysis]
10 Pajic M, Scarlett CJ, Chang DK, Sutherland RL, Biankin AV. Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet 2011;130:93-101. [PMID: 21516344 DOI: 10.1007/s00439-011-0990-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
11 Arslan C, Dizdar O, Altundag K. Pharmacotherapy of triple-negative breast cancer. Expert Opinion on Pharmacotherapy 2009;10:2081-93. [DOI: 10.1517/14656560903117309] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
12 Márquez-Rodas I, López-Tarruella S, Jerez Y, Cavanagh M, Custodio S, López-Trabada D, Moya B, Pérez S, Rupérez AB, Martín M. Evaluation of a heredofamilial cancer unit in increasing family history collection and genetic counseling referrals among Spanish oncologists at a university hospital. J Genet Couns 2014;23:108-13. [PMID: 23771728 DOI: 10.1007/s10897-013-9617-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Deng M, Chen H, Zhu X, Luo M, Zhang K, Xu C, Hu K, Cheng P, Zhou J, Zheng S, Chen Y. Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China. Int J Cancer 2019;145:1517-28. [DOI: 10.1002/ijc.32184] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
14 Lemmo S, Atefi E, Luker GD, Tavana H. Optimization of Aqueous Biphasic Tumor Spheroid Microtechnology for Anti-Cancer Drug Testing in 3D Culture. Cell Mol Bioeng 2014;7:344-54. [PMID: 25221631 DOI: 10.1007/s12195-014-0349-4] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
15 Atipairin A, Canyuk B, Ratanaphan A. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. Breast Cancer Res Treat 2011;126:203-9. [PMID: 20878461 DOI: 10.1007/s10549-010-1182-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
16 Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011;3:66-74. [PMID: 21278454 DOI: 10.1093/jmcb/mjq055] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
17 Francken AB, Schouten PC, Bleiker EM, Linn SC, Rutgers EJ. Breast cancer in women at high risk: the role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. Breast 2013;22:561-8. [PMID: 23972475 DOI: 10.1016/j.breast.2013.07.045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
18 Gornstein EL, Sandefur S, Chung JH, Gay LM, Holmes O, Erlich RL, Soman S, Martin LK, Rose AV, Stephens PJ, Ross JS, Miller VA, Ali SM, Blau S. BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clin Breast Cancer 2018;18:184-8. [PMID: 29325860 DOI: 10.1016/j.clbc.2017.12.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
19 Anders CK, Abramson V, Tan T, Dent R. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. Am Soc Clin Oncol Educ Book 2016;35:34-42. [PMID: 27249684 DOI: 10.1200/EDBK_159135] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
20 Cronin-Fenton DP, Kjærsgaard A, Nørgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L, Telford C, Lewis J, Tyczynski JE, Sørensen HT. Clinical outcomes of female breast cancer according to BRCA mutation status. Cancer Epidemiol 2017;49:128-37. [PMID: 28601786 DOI: 10.1016/j.canep.2017.05.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Barquín M, Maximiano C, Pérez-barrios C, Sanchez-herrero E, Soriano M, Colmena M, García-espantaleón M, Tejerina González E, Gutierrez L, Sánchez Ruiz AC, Torrente M, Provencio M, Romero A. Peritoneal washing is an adequate source for somatic BRCA1/2 mutation testing in ovarian malignancies. Pathology - Research and Practice 2019;215:392-4. [DOI: 10.1016/j.prp.2018.10.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hemel D, Domchek SM. Breast cancer predisposition syndromes. Hematol Oncol Clin North Am 2010;24:799-814. [PMID: 20816575 DOI: 10.1016/j.hoc.2010.06.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
23 Dizdar O, Altundag K. Current and emerging treatment options in triple-negative breast cancer. Oncol Rev 2010;4:5-13. [DOI: 10.1007/s12156-009-0031-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Agnese DM, Pollock RE. Breast Cancer Genetic Counseling: A Surgeon's Perspective. Front Surg 2016;3:4. [PMID: 26858951 DOI: 10.3389/fsurg.2016.00004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
25 Lin Z, Liu J, Peng L, Zhang D, Jin M, Wang J, Xue J, Liu H, Zhang T. Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report. BMC Cancer. 2018;18:1253. [PMID: 30547773 DOI: 10.1186/s12885-018-5182-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
26 Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, Garber JE, Richardson AL. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. Breast Cancer Res 2010;12:R95. [PMID: 21080930 DOI: 10.1186/bcr2776] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
27 Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. Nat Commun. 2017;8:319. [PMID: 28831036 DOI: 10.1038/s41467-017-00388-9] [Cited by in Crossref: 116] [Cited by in F6Publishing: 93] [Article Influence: 29.0] [Reference Citation Analysis]
28 Scott D, Friedman S, Telli ML, Kurian AW. Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. JCO Oncol Pract 2020;16:e37-55. [PMID: 31613719 DOI: 10.1200/JOP.19.00221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
29 Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5. [PMID: 21819606 DOI: 10.1186/1897-4287-9-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
30 Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, Rochlitz C, Zanetti-Dällenbach R. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget 2017;8:75617-26. [PMID: 29088896 DOI: 10.18632/oncotarget.18118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
31 Euhus D, Robinson L. Genetic Counseling and Genetic Testing in the Preoperative Evaluation of Breast Cancer Patients. Curr Breast Cancer Rep 2012;4:102-9. [DOI: 10.1007/s12609-012-0071-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Kriege M, Jager A, Hooning MJ, Huijskens E, Blom J, van Deurzen CH, Bontenbal M, Collee JM, Menke-Pluijmers MB, Martens JW, Seynaeve C. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer 2012;118:899-907. [PMID: 21761396 DOI: 10.1002/cncr.26351] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
33 Zhou L, Xu S, Yin W, Lin Y, Du Y, Jiang Y, Wang Y, Zhang J, Wu Z, Lu J. Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. Oncotarget 2017;8:79305-14. [PMID: 29108309 DOI: 10.18632/oncotarget.17954] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
34 Klinakis A, Karagiannis D, Rampias T. Targeting DNA repair in cancer: current state and novel approaches. Cell Mol Life Sci 2020;77:677-703. [PMID: 31612241 DOI: 10.1007/s00018-019-03299-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
35 El Adoui M, Drisis S, Benjelloun M. Multi-input deep learning architecture for predicting breast tumor response to chemotherapy using quantitative MR images. Int J CARS 2020;15:1491-500. [DOI: 10.1007/s11548-020-02209-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Yardley DA, Shipley DL, Peacock NW, Shastry M, Midha R, Priego VM, Hainsworth JD. Phase I/II trial of neoadjuvant sunitinib administered with weekly paclitaxel/carboplatin in patients with locally advanced triple-negative breast cancer. Breast Cancer Res Treat 2015;152:557-67. [PMID: 26155975 DOI: 10.1007/s10549-015-3482-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
37 Chowdhury P, Ghosh U, Samanta K, Jaggi M, Chauhan SC, Yallapu MM. Bioactive nanotherapeutic trends to combat triple negative breast cancer. Bioact Mater 2021;6:3269-87. [PMID: 33778204 DOI: 10.1016/j.bioactmat.2021.02.037] [Reference Citation Analysis]
38 Alexander BM, Sprott K, Farrow DA, Wang X, D'Andrea AD, Schnitt SJ, Collins LC, Weaver DT, Garber JE. DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer. Clin Cancer Res 2010;16:5796-804. [PMID: 21138871 DOI: 10.1158/1078-0432.CCR-10-0292] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
39 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014;25:1871-88. [PMID: 25234545 DOI: 10.1093/annonc/mdu385] [Cited by in Crossref: 252] [Cited by in F6Publishing: 222] [Article Influence: 36.0] [Reference Citation Analysis]
40 Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E. Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol Lett 2014;7:278-84. [PMID: 24348864 DOI: 10.3892/ol.2013.1684] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
41 Trainer AH, Lewis CR, Tucker K, Meiser B, Friedlander M, Ward RL. The role of BRCA mutation testing in determining breast cancer therapy. Nat Rev Clin Oncol 2010;7:708-17. [DOI: 10.1038/nrclinonc.2010.175] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.7] [Reference Citation Analysis]
42 Staudacher L, Cottu P, Diéras V, Vincent-salomon A, Guilhaume M, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga J. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Annals of Oncology 2011;22:848-56. [DOI: 10.1093/annonc/mdq461] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
43 Carey LA. Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer. J Clin Oncol 2010;28:361-3. [PMID: 20008634 DOI: 10.1200/JCO.2009.24.0838] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
44 Pal T, Vadaparampil ST. Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control 2012;19:255-66. [PMID: 23037493 DOI: 10.1177/107327481201900402] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
45 Drost RM, Jonkers J. Preclinical mouse models for BRCA1-associated breast cancer. Br J Cancer 2009;101:1651-7. [PMID: 19904273 DOI: 10.1038/sj.bjc.6605350] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
46 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
47 Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, Mierzwa T, Szwiec M, Wisniowski R, Siolek M, Dent R, Lubinski J, Narod S. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28:375-9. [PMID: 20008645 DOI: 10.1200/JCO.2008.20.7019] [Cited by in Crossref: 365] [Cited by in F6Publishing: 174] [Article Influence: 30.4] [Reference Citation Analysis]
48 Ogata H, Kikuchi Y, Natori K, Shiraga N, Kobayashi M, Magoshi S, Saito F, Osaku T, Kanazawa S, Kubota Y, Murakami Y, Kaneko H. Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature. Medicine (Baltimore) 2015;94:e1756. [PMID: 26496295 DOI: 10.1097/MD.0000000000001756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
49 Goel AK, Nandy M, Sharma G. Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results. Indian J Med Paediatr Oncol 2010;31:76-8. [PMID: 21206711 DOI: 10.4103/0971-5851.73588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
50 Bergin ART, Loi S. Triple-negative breast cancer: recent treatment advances. F1000Res 2019;8:F1000 Faculty Rev-1342. [PMID: 31448088 DOI: 10.12688/f1000research.18888.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 19.0] [Reference Citation Analysis]
51 Cobleigh MA. Other options in the treatment of advanced breast cancer. Semin Oncol 2011;38 Suppl 2:S11-6. [PMID: 21600380 DOI: 10.1053/j.seminoncol.2011.04.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
52 Raphael J, Mazouni C, Caron O, Ferchiou M, Delaloge S. Should BRCA2 mutation carriers avoid neoadjuvant chemotherapy? Med Oncol 2014;31. [DOI: 10.1007/s12032-014-0850-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
53 Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-692. [PMID: 20877296 DOI: 10.1038/nrclinonc.2010.154] [Cited by in Crossref: 495] [Cited by in F6Publishing: 463] [Article Influence: 45.0] [Reference Citation Analysis]
54 Moiseyenko VM, Dolmatov GD, Moiseyenko FV, Ivantsov AO, Volkov NM, Chubenko VA, Abduloeva NK, Bogdanov AA, Sokolenko AP, Imyanitov EN. High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation. Med Oncol 2015;32. [DOI: 10.1007/s12032-015-0514-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
55 Metcalfe K, Lynch HT, Foulkes WD, Tung N, Olopade OI, Eisen A, Lerner-Ellis J, Snyder C, Kim SJ, Sun P, Narod SA. Oestrogen receptor status and survival in women with BRCA2-associated breast cancer. Br J Cancer 2019;120:398-403. [PMID: 30723304 DOI: 10.1038/s41416-019-0376-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
56 Mancini P, Angeloni A, Risi E, Orsi E, Mezi S. Standard of care and promising new agents for triple negative metastatic breast cancer. Cancers (Basel) 2014;6:2187-223. [PMID: 25347122 DOI: 10.3390/cancers6042187] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
57 Dębska-Szmich S, Krakowska M, Czernek U, Habib-Lisik M, Zięba A, Potemski P. The role of preoperative systemic treatment in patients with breast cancer. Contemp Oncol (Pozn) 2016;20:93-101. [PMID: 27358586 DOI: 10.5114/wo.2016.60067] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
58 Lacroix-triki M, Geyer FC, Weigelt B, Reis-filho JS. Triple-Negative and Basal-like Carcinoma. Breast Pathology. Elsevier; 2012. pp. 446-78. [DOI: 10.1016/b978-1-4377-0604-8.00024-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
59 Bengala C. Recent advances in managing triple-negative breast cancers. F1000 Med Rep 2009;1:75. [PMID: 20948704 DOI: 10.3410/M1-75] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
60 Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012;30:1879-87. [PMID: 22454417 DOI: 10.1200/JCO.2011.38.2010] [Cited by in Crossref: 261] [Cited by in F6Publishing: 171] [Article Influence: 29.0] [Reference Citation Analysis]
61 Kordek R, Potemski P, Kusinska R, Pluciennik E, Bednarek A. Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res 2010;29:39. [PMID: 20426817 DOI: 10.1186/1756-9966-29-39] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
62 Imyanitov EN. Breast cancer therapy for BRCA1 carriers: moving towards platinum standard? Hered Cancer Clin Pract 2009;7:8. [PMID: 19379506 DOI: 10.1186/1897-4287-7-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
63 Rodriguez AA, Makris A, Wu MF, Rimawi M, Froehlich A, Dave B, Hilsenbeck SG, Chamness GC, Lewis MT, Dobrolecki LE, Jain D, Sahoo S, Osborne CK, Chang JC. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat 2010;123:189-96. [PMID: 20582464 DOI: 10.1007/s10549-010-0983-z] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
64 Johns AL, Miller DK, Simpson SH, Gill AJ, Kassahn KS, Humphris JL, Samra JS, Tucker K, Andrews L, Chang DK, Waddell N, Pajic M, Pearson JV, Grimmond SM, Biankin AV, Zeps N. Returning individual research results for genome sequences of pancreatic cancer. Genome Med 2014;6:42. [PMID: 24963353 DOI: 10.1186/gm558] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
65 Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer 2012;12:801-17. [PMID: 23175119 DOI: 10.1038/nrc3399] [Cited by in Crossref: 593] [Cited by in F6Publishing: 517] [Article Influence: 74.1] [Reference Citation Analysis]
66 Ferrario C, Batist G. Advances in the approach to novel drug clinical development for breast cancer. Expert Opin Drug Discov 2014;9:647-68. [PMID: 24758225 DOI: 10.1517/17460441.2014.911282] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
67 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
68 Euhus D. Genetic testing today. Ann Surg Oncol 2014;21:3209-15. [PMID: 25029991 DOI: 10.1245/s10434-014-3906-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
69 Somasundaram V, Srinivas P. Insights into the targeted elimination of BRCA1-defective cancer stem cells: TARGETING BRCA1-DEFECTIVE CANCER STEM CELLS. Med Res Rev 2012;32:948-67. [DOI: 10.1002/med.20229] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
70 Hurley J, Reis IM, Rodgers SE, Gomez-fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 2013;138:783-94. [DOI: 10.1007/s10549-013-2497-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
71 Kim SI, Sohn J, Koo JS, Park SH, Park HS, Park BW. Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer. Oncology 2010;79:324-30. [DOI: 10.1159/000322192] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
72 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
73 Icli F, Akbulut H, Onur H, Yalcin B, Demirkazık A, Şenler FÇ. Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up). The Breast 2011;20:155-7. [DOI: 10.1016/j.breast.2010.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
74 Larsen MJ, Thomassen M, Gerdes AM, Kruse TA. Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) 2014;8:145-55. [PMID: 25368521 DOI: 10.4137/BCBCR.S18715] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
75 Imanishi S, Naoi Y, Shimazu K, Shimoda M, Kagara N, Tanei T, Miyake T, Kim SJ, Noguchi S. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC. Breast Cancer Res Treat 2019;174:627-37. [DOI: 10.1007/s10549-018-05120-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
76 Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145-1153. [PMID: 20100965 DOI: 10.1200/jco.2009.22.4725] [Cited by in Crossref: 642] [Cited by in F6Publishing: 333] [Article Influence: 58.4] [Reference Citation Analysis]
77 Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? Eur J Surg Oncol 2016;42:1780-6. [PMID: 27825710 DOI: 10.1016/j.ejso.2016.10.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
78 Riis ML. Management of patients with BRCA mutation from the point of view of a breast surgeon. Ann Med Surg (Lond) 2021;65:102311. [PMID: 33996049 DOI: 10.1016/j.amsu.2021.102311] [Reference Citation Analysis]
79 Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. J Am Coll Surg 2018;226:630-637.e1. [PMID: 29309945 DOI: 10.1016/j.jamcollsurg.2017.12.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
80 Drost R, Jonkers J. Opportunities and hurdles in the treatment of BRCA1-related breast cancer. Oncogene 2014;33:3753-63. [PMID: 23955079 DOI: 10.1038/onc.2013.329] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
81 Brunet J. Hereditary breast cancer and genetic counseling in young women. Breast Cancer Res Treat 2010;123 Suppl 1:7-9. [PMID: 20711663 DOI: 10.1007/s10549-010-1050-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
82 Lønning PE. Molecular basis for therapy resistance. Mol Oncol 2010;4:284-300. [PMID: 20466604 DOI: 10.1016/j.molonc.2010.04.005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
83 Price M, Monteiro AN. Fine tuning chemotherapy to match BRCA1 status. Biochem Pharmacol 2010;80:647-53. [PMID: 20510205 DOI: 10.1016/j.bcp.2010.05.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
84 Liu Y, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Association between CHEK2 H371Y mutation and response to neoadjuvant chemotherapy in women with breast cancer. BMC Cancer 2015;15:194. [PMID: 25884806 DOI: 10.1186/s12885-015-1203-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
85 Balko JM, Stricker TP, Arteaga CL. The genomic map of breast cancer: which roads lead to better targeted therapies? Breast Cancer Res 2013;15:209. [PMID: 23905624 DOI: 10.1186/bcr3435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
86 Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 2015;8:519-28. [PMID: 25750544 DOI: 10.2147/OTT.S30793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
87 Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 2013;19:6322-8. [PMID: 24077350 DOI: 10.1158/1078-0432.CCR-13-1975] [Cited by in Crossref: 119] [Cited by in F6Publishing: 77] [Article Influence: 14.9] [Reference Citation Analysis]
88 Diaz-Cruz ES, Cabrera MC, Nakles R, Rutstein BH, Furth PA. BRCA1 deficient mouse models to study pathogenesis and therapy of triple negative breast cancer. Breast Dis 2010;32:85-97. [PMID: 21778574 DOI: 10.3233/BD-2010-0308] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
89 Moiseyenko VM, Protsenko SA, Brezhnev NV, Maximov SY, Gershveld ED, Hudyakova MA, Lobeiko OS, Gergova MM, Krzhivitskiy PI, Semionov II, Matsko DE, Iyevleva AG, Sokolenko AP, Sherina NY, Kuligina ES, Suspitsin EN, Togo AV, Imyanitov EN. High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases. Cancer Genetics and Cytogenetics 2010;197:91-4. [DOI: 10.1016/j.cancergencyto.2009.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
90 La Belle A, Khatib J, Schiemann WP, Vinayak S. Role of Platinum in Early-Stage Triple-Negative Breast Cancer. Curr Treat Options Oncol 2017;18:68. [PMID: 29110096 DOI: 10.1007/s11864-017-0506-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
91 Atipairin A, Canyuk B, Ratanaphan A. Cisplatin Affects the Conformation of Apo Form, not Holo Form, of BRCA1 RING Finger Domain and Confers Thermal Stability. Chemistry & Biodiversity 2010;7:1949-67. [DOI: 10.1002/cbdv.200900308] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
92 Azim HA, Ghosn M, Oualla K, Kassem L. Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020. Breast J 2020;26:69-80. [PMID: 31872557 DOI: 10.1111/tbj.13713] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
93 Ali RMM, Mcintosh SA, Savage KI. Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy. Genes Chromosomes Cancer 2021;60:358-72. [DOI: 10.1002/gcc.22921] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
94 Zha M, Tian T, Xu W, Liu S, Jia J, Wang L, Yan Q, Li N, Yu J, Huang L. The circadian clock gene Bmal1 facilitates cisplatin-induced renal injury and hepatization. Cell Death Dis 2020;11:446. [PMID: 32522976 DOI: 10.1038/s41419-020-2655-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Chalasani P, Livingston R. Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. Oncologist 2013;18:909-16. [PMID: 23881989 DOI: 10.1634/theoncologist.2013-0039] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
96 Galanina N, Bossuyt V, Harris LN. Molecular Predictors of Response to Therapy for Breast Cancer. The Cancer Journal 2011;17:96-103. [DOI: 10.1097/ppo.0b013e318212dee3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
97 Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res. 2010;16:4517-4526. [PMID: 20823142 DOI: 10.1158/1078-0432.ccr-10-0526] [Cited by in Crossref: 69] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
98 Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. Chemother Res Pract 2011;2011:696208. [PMID: 22312556 DOI: 10.1155/2011/696208] [Cited by in Crossref: 18] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
99 Foulkes WD. BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective. Clin Genet 2014;85:1-4. [PMID: 24116874 DOI: 10.1111/cge.12291] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
100 Dandawate P, Khan E, Padhye S, Gaba H, Sinha S, Deshpande J, Venkateswara Swamy K, Khetmalas M, Ahmad A, Sarkar FH. Synthesis, characterization, molecular docking and cytotoxic activity of novel plumbagin hydrazones against breast cancer cells. Bioorganic & Medicinal Chemistry Letters 2012;22:3104-8. [DOI: 10.1016/j.bmcl.2012.03.060] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
101 Díaz-Casas SE, Castilla-Tarra JA, Pena-Torres E, Orozco-Ospino M, Mendoza-Diaz S, Nuñez-Lemus M, Garcia-Angulo O, Garcia-Mora M, Guzman-AbiSaab L, Lehmann-Mosquera C, Angel-Aristizabal J, Duarte-Torres C, Vergel-Martinez JC. Pathological Response to Neoadjuvant Chemotherapy and the Molecular Classification of Locally Advanced Breast Cancer in a Latin American Cohort. Oncologist 2019;24:e1360-70. [PMID: 31346133 DOI: 10.1634/theoncologist.2019-0300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
102 Hambrecht A, Jandial R, Neman J. Emerging role of brain metastases in the prognosis of breast cancer patients. Breast Cancer (Dove Med Press) 2011;3:79-91. [PMID: 24367178 DOI: 10.2147/BCTT.S19967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
103 Telli ML, Sledge GW. The future of breast cancer systemic therapy: the next 10 years. J Mol Med (Berl) 2015;93:119-25. [PMID: 25566982 DOI: 10.1007/s00109-014-1238-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
104 Elsakov P, Kurtinaitis J, Petraitis S, Ostapenko V, Razumas M, Razumas T, Meskauskas R, Petrulis K, Luksite A, Lubiński J, Górski B, Narod SA, Gronwald J. The contribution of founder mutations in BRCA1 to breast and ovarian cancer in Lithuania. Clin Genet 2010;78:373-6. [PMID: 20345474 DOI: 10.1111/j.1399-0004.2010.01404.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
105 Atipairin A, Ratanaphan A. In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer (Auckl) 2011;5:201-8. [PMID: 22084573 DOI: 10.4137/BCBCR.S8184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
106 Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E; European School of Oncology., European Society of Medical Oncology. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014;23:489-502. [PMID: 25244983 DOI: 10.1016/j.breast.2014.08.009] [Cited by in Crossref: 190] [Cited by in F6Publishing: 155] [Article Influence: 27.1] [Reference Citation Analysis]
107 Hartmann S, Reimer T, Gerber B. Management of early invasive breast cancer in very young women (<35 years). Clin Breast Cancer 2011;11:196-203. [PMID: 21752723 DOI: 10.1016/j.clbc.2011.06.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
108 Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, Schiff D, Moran MS, Golhar R, Chen C, Moore D, Ganesan S. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:e677-83. [PMID: 22520477 DOI: 10.1016/j.ijrobp.2012.01.089] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
109 Amos KD, Adamo B, Anders CK. Triple-negative breast cancer: an update on neoadjuvant clinical trials. Int J Breast Cancer 2012;2012:385978. [PMID: 22461984 DOI: 10.1155/2012/385978] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
110 Koch M, Hanl M, Wiese M. Feature extraction via composite scoring and voting in breast cancer. Breast Cancer Res Treat 2012;135:307-18. [PMID: 22833200 DOI: 10.1007/s10549-012-2177-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
111 Márquez-Rodas I, López-Trabada D, Rupérez Blanco AB, Custodio Cabello S, Peligros Gómez MI, Orera Clemente M, Calvo FA, Martín M. Family history record and hereditary cancer risk perception according to National Cancer Institute criteria in a Spanish medical oncology service: a retrospective study. Oncology 2012;82:30-4. [PMID: 22286392 DOI: 10.1159/000335960] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
112 Ratanaphan A. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer. Int J Mol Sci 2012;13:14898-916. [PMID: 23203101 DOI: 10.3390/ijms131114898] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
113 Vanags A, Strumfa I, Gardovskis A, Borošenko V, Aboliņš A, Teibe U, Trofimovičs G, Miklaševičs E, Gardovskis J. Population screening for hereditary and familial cancer syndromes in Valka district of Latvia. Hered Cancer Clin Pract 2010;8:8. [PMID: 21034437 DOI: 10.1186/1897-4287-8-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
114 Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. Breast Cancer Res Treat 2021;189:187-202. [PMID: 34173924 DOI: 10.1007/s10549-021-06307-3] [Reference Citation Analysis]
115 Cohen MS, Cai S, Xie Y, Forrest ML. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg 2009;198:781-6. [PMID: 19969129 DOI: 10.1016/j.amjsurg.2009.07.032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
116 Nasr KE, Osman MA, Elkady MS, Ellithy MA. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med. 2015;3:284. [PMID: 26697444 DOI: 10.3978/j.issn.2305-5839.2015.11.14] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
117 Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012;2:366-75. [PMID: 22576213 DOI: 10.1158/2159-8290.CD-11-0206] [Cited by in Crossref: 250] [Cited by in F6Publishing: 129] [Article Influence: 27.8] [Reference Citation Analysis]
118 Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current Opinion in Oncology 2011;23:566-77. [DOI: 10.1097/cco.0b013e32834bf8ae] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
119 Tryfonidis K, Senkus E, Cardoso MJ, Cardoso F. Management of locally advanced breast cancer-perspectives and future directions. Nat Rev Clin Oncol 2015;12:147-62. [PMID: 25668732 DOI: 10.1038/nrclinonc.2015.13] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
120 Bertucci F, Finetti P, Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med. 2012;12:96-110. [PMID: 22082486 DOI: 10.2174/156652412798376134] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
121 Tacconi EM, Badie S, De Gregoriis G, Reisländer T, Lai X, Porru M, Folio C, Moore J, Kopp A, Baguña Torres J, Sneddon D, Green M, Dedic S, Lee JW, Batra AS, Rueda OM, Bruna A, Leonetti C, Caldas C, Cornelissen B, Brino L, Ryan A, Biroccio A, Tarsounas M. Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance. EMBO Mol Med 2019;11:e9982. [PMID: 31273933 DOI: 10.15252/emmm.201809982] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
122 de Mestier L, Danset J, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer 2016;23:T57-67. [DOI: 10.1530/erc-16-0269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
123 Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017;8:79175-87. [PMID: 29108297 DOI: 10.18632/oncotarget.16577] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
124 Trusler O, Goodwin J, Laslett AL. BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. Biochim Biophys Acta Rev Cancer 2021;1875:188459. [PMID: 33129865 DOI: 10.1016/j.bbcan.2020.188459] [Reference Citation Analysis]
125 Peshkin BN, Alabek ML, Isaacs C. BRCA1/2 mutations and triple negative breast cancers. Breast Dis. 2010;32:25-33. [PMID: 21778580 DOI: 10.3233/bd-2010-0306] [Cited by in Crossref: 68] [Cited by in F6Publishing: 48] [Article Influence: 7.6] [Reference Citation Analysis]
126 Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Platinum-based therapy for triple-negative breast cancer treatment: A meta-analysis. Mol Clin Oncol 2015;3:720-4. [PMID: 26137293 DOI: 10.3892/mco.2015.518] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
127 Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 2011;18:180-90. [PMID: 21874117 DOI: 10.3747/co.v18i4.913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
128 Garcia C, Powell CB. A comprehensive approach to the identification and management of the BRCA patient. Obstet Gynecol Surv 2015;70:131-43. [PMID: 25671374 DOI: 10.1097/OGX.0000000000000156] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
129 Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Breast Cancer Res Treat 2019;173:385-95. [PMID: 30350268 DOI: 10.1007/s10549-018-5015-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
130 Bayraktar S, Arun B. BRCA mutation genetic testing implications in the United States. Breast 2017;31:224-32. [PMID: 27931006 DOI: 10.1016/j.breast.2016.11.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 5.4] [Reference Citation Analysis]
131 Dine J, Deng CX. Mouse models of BRCA1 and their application to breast cancer research. Cancer Metastasis Rev 2013;32:25-37. [PMID: 23093327 DOI: 10.1007/s10555-012-9403-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
132 Fasching PA, Loibl S, Hu C, Hart SN, Shimelis H, Moore R, Schem C, Tesch H, Untch M, Hilfrich J, Rezai M, Gerber B, Costa SD, Blohmer JU, Fehm T, Huober J, Liedtke C, Weinshilboum RM, Wang L, Ingle JN, Müller V, Nekljudova V, Weber KE, Rack B, Rübner M, von Minckwitz G, Couch FJ. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. J Clin Oncol 2018;36:2281-7. [PMID: 29791287 DOI: 10.1200/JCO.2017.77.2285] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
133 Biankin AV, Hudson TJ. Somatic variation and cancer: therapies lost in the mix. Hum Genet 2011;130:79-91. [DOI: 10.1007/s00439-011-1010-0] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
134 Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58. [PMID: 21080741 DOI: 10.2165/11538150-000000000-00000] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
135 Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 2013;24:1219-25. [PMID: 23223332 DOI: 10.1093/annonc/mds603] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
136 Pons DG, Nadal-Serrano M, Torrens-Mas M, Valle A, Oliver J, Roca P. UCP2 inhibition sensitizes breast cancer cells to therapeutic agents by increasing oxidative stress. Free Radic Biol Med 2015;86:67-77. [PMID: 25960046 DOI: 10.1016/j.freeradbiomed.2015.04.032] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 9.7] [Reference Citation Analysis]
137 Wang D, Feng J, Xu B. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer. Future Oncol 2019;15:2779-90. [PMID: 31293180 DOI: 10.2217/fon-2019-0165] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
138 Iyevleva AG, Suspitsin EN, Kroeze K, Gorodnova TV, Sokolenko AP, Buslov KG, Voskresenskiy DA, Togo AV, Kovalenko SP, Stoep Nv, Devilee P, Imyanitov EN. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett 2010;298:258-63. [PMID: 20727672 DOI: 10.1016/j.canlet.2010.07.013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
139 Chang DK, Grimmond SM, Biankin AV. Pancreatic cancer genomics. Curr Opin Genet Dev. 2014;24:74-81. [PMID: 24480245 DOI: 10.1016/j.gde.2013.12.001] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
140 Jamieson NB, Chang DK, Biankin AV. Cancer Genetics and Implications for Clinical Management. Surgical Clinics of North America 2015;95:919-34. [DOI: 10.1016/j.suc.2015.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
141 Turiján-Espinoza E, Ruíz-Rodríguez VM, Uresti-Rivera EE, Martínez-Leija E, Zermeño-Nava JJ, Guel-Pañola A, Romano-Moreno S, Vargas-Morales JM, Portales-Pérez DP. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients. Cancer Chemother Pharmacol 2021;87:843-53. [PMID: 33740100 DOI: 10.1007/s00280-021-04244-y] [Reference Citation Analysis]
142 Smith KL, Isaacs C. BRCA mutation testing in determining breast cancer therapy. Cancer J 2011;17:492-9. [PMID: 22157293 DOI: 10.1097/PPO.0b013e318238f579] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
143 Park JH, Ahn JH, Kim SB. How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open 2018;3:e000357. [PMID: 29765774 DOI: 10.1136/esmoopen-2018-000357] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 17.7] [Reference Citation Analysis]
144 Ahrens P, Kreipe HH. [BRCA1- and BRCA2- associated breast carcinomas]. Pathologe 2009;30 Suppl 2:207-9. [PMID: 19795125 DOI: 10.1007/s00292-009-1223-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
145 Silver DP, Livingston DM. Mechanisms of BRCA1 tumor suppression. Cancer Discov 2012;2:679-84. [PMID: 22843421 DOI: 10.1158/2159-8290.CD-12-0221] [Cited by in Crossref: 86] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
146 Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY, Lee CY, Quah SI, Fow C, Chung C, So I, Tan BS, Choo HL, Rosli R, Cheong S, Leong C. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 2011;128:301-13. [DOI: 10.1007/s10549-010-1055-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
147 Greenberg S, Stopeck A, Rugo HS. Systemic treatment of early breast cancer-a biological perspective: Systemic Treatment of Early Breast Cancer. J Surg Oncol 2011;103:619-26. [DOI: 10.1002/jso.21842] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
148 Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14:R110. [PMID: 22817698 DOI: 10.1186/bcr3231] [Cited by in Crossref: 129] [Cited by in F6Publishing: 111] [Article Influence: 14.3] [Reference Citation Analysis]
149 Marino MA, Riedl CC, Bernathova M, Bernhart C, Baltzer PAT, Helbich TH, Pinker K. Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System. Eur J Radiol 2018;106:150-9. [PMID: 30150038 DOI: 10.1016/j.ejrad.2018.07.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
150 Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer. J Clin Oncol 2017;35:3800-6. [PMID: 28820644 DOI: 10.1200/JCO.2017.73.6314] [Cited by in Crossref: 143] [Cited by in F6Publishing: 62] [Article Influence: 35.8] [Reference Citation Analysis]
151 Francis PA. Optimal adjuvant therapy for very young breast cancer patients. The Breast 2011;20:297-302. [DOI: 10.1016/j.breast.2011.05.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
152 Wang C, Zhang J, Wang Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y. Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. Ann Oncol 2015;26:523-8. [PMID: 25480878 DOI: 10.1093/annonc/mdu559] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
153 Węsierska-Gądek J, Składanowski A. Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes. Future Med Chem 2012;4:51-72. [PMID: 22168164 DOI: 10.4155/fmc.11.175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
154 Metro G, Zheng Z, Fabi A, Schell M, Antoniani B, Mottolese M, Monteiro AN, Vici P, Lara Rivera S, Boulware D, Cognetti F, Bepler G. In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy. Cancer Invest 2010;28:172-80. [PMID: 19968494 DOI: 10.3109/07357900903095722] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
155 Kriege M, Seynaeve C, Meijers-heijboer H, Collee JM, Menke-pluymers MB, Bartels CC, Tilanus-linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG. Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JCO 2009;27:3764-71. [DOI: 10.1200/jco.2008.19.9067] [Cited by in Crossref: 75] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
156 Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010;4:209-29. [PMID: 20537966 DOI: 10.1016/j.molonc.2010.04.006] [Cited by in Crossref: 181] [Cited by in F6Publishing: 174] [Article Influence: 16.5] [Reference Citation Analysis]
157 Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22:3764-3773. [PMID: 26957554 DOI: 10.1158/1078-0432.ccr-15-2477] [Cited by in Crossref: 343] [Cited by in F6Publishing: 164] [Article Influence: 68.6] [Reference Citation Analysis]
158 Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013;11:2. [PMID: 23548133 DOI: 10.1186/1897-4287-11-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
159 Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol 2010;2:a003236. [PMID: 20719876 DOI: 10.1101/cshperspect.a003236] [Cited by in Crossref: 133] [Cited by in F6Publishing: 114] [Article Influence: 12.1] [Reference Citation Analysis]
160 Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F. Do platinum salts fit all triple negative breast cancers? Cancer Treat Rev 2016;48:34-41. [PMID: 27343437 DOI: 10.1016/j.ctrv.2016.06.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
161 Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33:13-21. [PMID: 25092775 DOI: 10.1200/jco.2014.57.0572] [Cited by in Crossref: 458] [Cited by in F6Publishing: 226] [Article Influence: 65.4] [Reference Citation Analysis]
162 Vargas AC, Reis-Filho JS, Lakhani SR. Phenotype-genotype correlation in familial breast cancer. J Mammary Gland Biol Neoplasia 2011;16:27-40. [PMID: 21400086 DOI: 10.1007/s10911-011-9204-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
163 Koh MZ, Ho WY, Yeap SK, Ali NM, Boo L, Alitheen NB. Regulation of Cellular and Cancer Stem Cell-Related Putative Gene Expression of Parental and CD44+CD24- Sorted MDA-MB-231 Cells by Cisplatin. Pharmaceuticals (Basel) 2021;14:391. [PMID: 33919109 DOI: 10.3390/ph14050391] [Reference Citation Analysis]
164 van der Groep P, van der Wall E, van Diest PJ. Pathology of hereditary breast cancer. Cell Oncol (Dordr). 2011;34:71-88. [PMID: 21336636 DOI: 10.1007/s13402-011-0010-3] [Cited by in Crossref: 80] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
165 Li SX, Sjolund A, Harris L, Sweasy JB. DNA repair and personalized breast cancer therapy. Environ Mol Mutagen 2010;51:897-908. [PMID: 20872853 DOI: 10.1002/em.20606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
166 Jaspers JE, Rottenberg S, Jonkers J. Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim Biophys Acta. 2009;1796:266-280. [PMID: 19616605 DOI: 10.1016/j.bbcan.2009.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 20] [Article Influence: 0.3] [Reference Citation Analysis]
167 Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Triple-negative breast cancer. Wien Med Wochenschr 2010;160:174-81. [PMID: 20473728 DOI: 10.1007/s10354-010-0773-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
168 Guan X, Ma F, Fan Y, Zhu W, Hong R, Xu B. Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anticancer Drugs 2015;26:894-901. [PMID: 26086398 DOI: 10.1097/CAD.0000000000000260] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
169 Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale AL, van de Vijver MJ, Nederlof PM, Jonkers J. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010;10:654. [PMID: 21118481 DOI: 10.1186/1471-2407-10-654] [Cited by in Crossref: 47] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
170 Shahda S, Timms KM, Ibrahim AA, Reid JE, Cramer HM, Radovich M, Ibrahim S, Allen B, O’neil BH. Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy. JCO Precision Oncology 2018. [DOI: 10.1200/po.17.00087] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
171 Lou SK, Grenier S, Care M, McCuaig J, Stockley TL, Clarke B, Ruff HM, Boerner SL. Validation of BRCA testing on cytologic samples of high-grade serous carcinoma. Cancer Cytopathol 2021. [PMID: 34157791 DOI: 10.1002/cncy.22484] [Reference Citation Analysis]
172 Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet 2016;293:247-69. [PMID: 26341644 DOI: 10.1007/s00404-015-3859-y] [Cited by in Crossref: 178] [Cited by in F6Publishing: 159] [Article Influence: 29.7] [Reference Citation Analysis]
173 Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W. Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2011;458:55-64. [PMID: 20941507 DOI: 10.1007/s00428-010-0988-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
174 Euhus DM, Robinson L. Genetic Predisposition Syndromes and Their Management. Surgical Clinics of North America 2013;93:341-62. [DOI: 10.1016/j.suc.2013.01.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
175 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
176 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
177 Telli ML, Ford JM. Novel treatment approaches for triple-negative breast cancer. Clin Breast Cancer 2010;10 Suppl 1:E16-22. [PMID: 20587403 DOI: 10.3816/CBC.2010.s.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
178 Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N. Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency. Sci Rep 2019;9:1644. [PMID: 30733539 DOI: 10.1038/s41598-018-38311-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
179 Vesprini D, Narod SA, Trachtenberg J, Crook J, Jalali F, Preiner J, Sridhar S, Bristow RG. The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Can Urol Assoc J 2011;5:E31-5. [PMID: 21470549 DOI: 10.5489/cuaj.10080] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
180 Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. Clinical Breast Cancer 2018;18:e1229-35. [DOI: 10.1016/j.clbc.2017.12.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
181 Constantinidou A, Jones RL, Reis-filho JS. Beyond triple-negative breast cancer: the need to define new subtypes. Expert Review of Anticancer Therapy 2014;10:1197-213. [DOI: 10.1586/era.10.50] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
182 Gelmon K, Dent R, Mackey J, Laing K, Mcleod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Annals of Oncology 2012;23:2223-34. [DOI: 10.1093/annonc/mds067] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 12.4] [Reference Citation Analysis]
183 Chartron E, Theillet C, Guiu S, Jacot W. Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data. Crit Rev Oncol Hematol 2019;133:58-73. [PMID: 30661659 DOI: 10.1016/j.critrevonc.2018.10.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
184 Ter Brugge P, Kristel P, van der Burg E, Boon U, de Maaker M, Lips E, Mulder L, de Ruiter J, Moutinho C, Gevensleben H, Marangoni E, Majewski I, Józwiak K, Kloosterman W, van Roosmalen M, Duran K, Hogervorst F, Turner N, Esteller M, Cuppen E, Wesseling J, Jonkers J. Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer. J Natl Cancer Inst 2016;108. [PMID: 27381626 DOI: 10.1093/jnci/djw148] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 15.6] [Reference Citation Analysis]
185 Assi HI, Assi RE, El Saghir NS. Emerging Biomarkers of the Future: Changing Clinical Practice for 2020. Curr Breast Cancer Rep 2016;8:60-72. [DOI: 10.1007/s12609-016-0214-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
186 Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, Biganzoli L, Di Leo A. Adjuvant systemic treatment for individual patients with triple negative breast cancer. The Breast 2011;20:S135-41. [DOI: 10.1016/s0960-9776(11)70311-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
187 Morovati A, Ahmadian S, Jafary H. Cytotoxic effects and apoptosis induction of cisplatin-loaded iron oxide nanoparticles modified with chitosan in human breast cancer cells. Mol Biol Rep 2019;46:5033-9. [PMID: 31278563 DOI: 10.1007/s11033-019-04954-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
188 Aktas BY, Guner G, Guven DC, Arslan C, Dizdar O. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. Expert Rev Anticancer Ther 2019;19:589-601. [PMID: 31181965 DOI: 10.1080/14737140.2019.1631162] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Willers H, Pfäffle HN, Zou L. Targeting Homologous Recombination Repair in Cancer. DNA Repair in Cancer Therapy. Elsevier; 2012. pp. 119-60. [DOI: 10.1016/b978-0-12-384999-1.10007-1] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
190 Pons DG, Torrens-Mas M, Nadal-Serrano M, Sastre-Serra J, Roca P, Oliver J. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents. Int J Biochem Cell Biol 2015;66:85-94. [PMID: 26232188 DOI: 10.1016/j.biocel.2015.07.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
191 Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clin Cancer Res. 2014;20:782-790. [PMID: 24536073 DOI: 10.1158/1078-0432.ccr-13-0583] [Cited by in Crossref: 186] [Cited by in F6Publishing: 116] [Article Influence: 26.6] [Reference Citation Analysis]
192 Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, Huang J, Zhang Z. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget 2016;7:70113-27. [PMID: 27659521 DOI: 10.18632/oncotarget.12158] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
193 Jamieson NB, Chang DK, Grimmond SM, Biankin AV. Can we move towards personalised pancreatic cancer therapy? Expert Rev Gastroenterol Hepatol 2014;8:335-8. [PMID: 24702631 DOI: 10.1586/17474124.2014.893820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]